Most recent update: Friday, September 21, 2018 - 15:00

Bariatric News - Cookies & privacy policy

You are here

T2DM breakthrough

Intestinal hormone receptors could correct T2DM

Novel molecules simultaneously stimulate two receptors

Researchers from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists from Indiana University and colleagues from the University of Cincinnati, have developed a new therapeutic approach for treatment of type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide), was observed to reduce weight and improve blood sugar.

The results were published in the journal Science Translational Medicine, and include data from clinical studies in partnership with Roche.

“Our results give us additional confidence that our combinatorial approach of modulating brain regulatory centres via natural gut hormone signals has superior potential for a transformative diabetes treatment”, said Professor Matthias Tschöp at the Helmholtz Diabetes Center.

GLP-1 and GIP are hormones that are formed by the digestive tract, which control food intake and numerous metabolic processes. Some of the actions, which are combined in one molecule for the first time, are already in use for the treatment of type 2 diabetes.

GLP-1 analogues, as well as DPP4 (dipeptidyl peptidase 4) inhibitors, which are thought to enhance GLP-1 action, are used to reduce blood sugar. The research teams have now succeeded in developing a molecular structure that combines the effects of the two hormones. These novel molecules simultaneously stimulate two receptors (GLP-1 and GIP) and consequently maximize metabolic effects compared to each of the individual molecules, or currently available medicines that are based on individual intestinal hormones.

The newly discovered GLP-1/GIP co-agonists lead to improved blood sugar levels and to a significant weight loss and lower blood fat. Importantly, the researchers observed that the new substance also improved metabolism in humans, in addition to beneficial effects they discovered in several animal models.

At the same time, there are indications that possible adverse effects, the most frequent of which are gastrointestinal complaints, are less common and less pronounced with this approach than with the individual hormones.

Dr Brian Finan

“This approach has to go through several more years of intense research, clinical testing, and safety evaluations, before these substances may become available for patients,” said Dr Brian Finan, the first author of the study, points out that there may be unprecedented potential: “We are quite excited about this new multi-functional agent approach and believe it could become an integral part of a next generation of personalized therapies for type 2 diabetes, as the ratio of the GLP-1 and GIP signal strengths could be adjusted depending on the individual needs of patients.”

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.